📋 Tender Overview
Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials
Precision Medicine At The Forefront Of Cancer Carein The Eu, Cancer Has A Devastating Impact On Millions; The Staggering Mortality Rates Make It A Leading Cause Of Death And Morbidity. In This Context, The Eu-Funded Prime-Rose Project Is Committed To The Mission Cancer Goal. Specifically, It Aims To Optimise Treatments And Enhance The Quality Of Life For Over 3 Million People By 2030. In Addition To Enhancing Access To Affordable, Life-Prolonging Treatments, The Project Will Conduct Precision Cancer Medicine Trials And Bridge Gaps In Healthcare Inequalities. Prime-Rose Relies On Drug Rediscovery Protocol-Like Trials, Ensuring A Bottom-Up, Clinician-Driven Approach To Bring Precision Medicine To The Forefront Of Cancer Care.
Funded Under
Health
Total Cost
€ 5 968 725,00
Eu Contribution
€ 5 968 725,00
Coordinated By
Oslo Universitetssykehus Hf
Norway
Start Date
1 July 2023
End Date
30 June 2028
